Boehringer Ingelheim
-
Vanderbilt-discovered cancer killing compound is now available through Boehringer Ingelheim open science portal opnMe
Researchers in the lab of Stephen Fesik, Orrin H. Ingram II Chair in Cancer Research, have added BI-0474 as the second molecule co-discovered by Vanderbilt to the open science portal opnMe.com, an initiative being driven by biopharmaceutical company Boehringer Ingelheim. Read MoreMay 30, 2024
-
Professor makes Vanderbilt-discovered cancer targeting molecule freely available to researchers through collaboration with Boehringer Ingelheim
Stephen Fesik’s discovery of a cancer-targeting molecule has been made freely accessible through opnMe for global researchers to advance research into cancer therapeutics. Read MoreNov 15, 2021
-
Vanderbilt, Boehringer Ingelheim announce partnership to develop therapies for psychiatric disorders
Boehringer Ingelheim and Vanderbilt Center for Neuroscience Drug Discovery today announced two new global agreements to investigate, develop and commercialize novel small molecules targeting two distinct G-protein coupled receptors known to engage in the modulation of certain brain circuitries, which are altered in neuropsychiatric conditions such as schizophrenia. Read MoreJan 3, 2019